The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. by Dapavo, P et al.
From the Depar
tology, Unive
Rudolfstiftung
University Vie
University, Vie
Drs Dapavo and
Funding sources:
Conflicts of intere
Accepted for pub
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plaque psoriasisPaolo Dapavo, MD,a Igor Vujic, MD,b,c Maria Teresa Fierro, MD,a
Pietro Quaglino, MD,a and Martina Sanlorenzo, MDa
Turin, Italy, and Vienna, AustriaBackground: The infliximab originator’s patent recently expired, leading to the production of biosimilar
versions of the drug. The biosimilars’ efficacy was not tested on patients with psoriasis but most regulatory
authorities approved their use in psoriasis because of an extrapolation of data from studies conducted in
other diseases.Objective: We sought to describe the use of the infliximab biosimilar (Remsima; CT-P13) in patients with
psoriasis.Methods: Objective (Psoriasis Area and Severity Index) and subjective (visual analog pain scale)
measurements of disease activity were collected in 2 cohorts of patients with moderate to severe plaque
psoriasis: cohort 1 patients switched from the infliximab originator to the infliximab biosimilar; and cohort
2 patients were infliximab-na€ıve and started on the infliximab biosimilar.Results: We observed no changes of Psoriasis Area and Severity Index and visual analog pain scale scores
in 30 patients who switched from the infliximab originator to the biosimilar. Four of 5 infliximab-na€ıve
patients who started infliximab biosimilar treatment achieved 75% improvement or better from baseline
Psoriasis Area and Severity Index score at the end of the induction phase.Limitations: Number of patients and length of follow-up was limited.Conclusions: Patients with psoriasis taking infliximab originator treatment can switch to the infliximab
biosimilar without experiencing a significant change in clinical response or additional adverse events. The
use of the infliximab biosimilar could reduce the growing pressure on health care budgets. ( J Am Acad
Dermatol 2016;75:736-9.)
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he infliximab originator (Remicade, Janssen
Biotech, Inc, Horsham, PA), an antietumor
necrosis factor-alfa monoclonal antibody,
has shown its efficacy in treating psoriasis but is
relatively expensive.1,2 Cheaper biosimilars (drugs
designed to have the same pharmacodynamic and
pharmacokinetic properties as their previously
licensed reference drugs) are available, but weretment of Medical Sciences, Section of Derma-
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lication April 25, 2016.not tested in patients with psoriasis. Most regula-
tory agencies have approved the use of infliximab
biosimilars for the treatment of psoriasis by extrap-
olating efficacy from studies in other diseases.5-8
Here, we describe our experience in the use of the
infliximab biosimilar Remsima (CT-P13, Celltrion,
Korea) in the treatment of patients affected by
moderate to severe plaque psoriasis.Reprint requests: Martina Sanlorenzo, MD, Department of Medical
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The study was approved by the local ethical
committee. All patients included in this study had a
diagnosis of moderate to severe plaque psoriasis,
signed the participation consent forms, and were
treated at the University of Turin (Italy) in the
period from July 1, 2015, to January 20, 2016.CAPSULE SUMMARY
d Infliximab biosimilars have shown
efficacy in other diseases but testing in
psoriasis has been limited.
d In our study, patients with psoriasis who
switched from the infliximab originator
to the infliximab biosimilar maintained
their clinical response and experienced
no additional adverse events.
d The infliximab biosimilar may be a viable
treatment option for patients with
psoriasis.The following data were
collected: age, gender, previ-
ous treatments, presence of
psoriatic arthritis, Psoriasis
Area and Severity Index
(PASI) and visual analog
scale for arthritic pain scores
at baseline and at each visit,
along with any adverse
events. Statistical analyses
were performed using soft-
ware (Stata 12.0, Stata Corp,
College Station, TX). Follow-
up time was calculated as the
time from the first cycle of
biosimilar use until the end
of the study. Comparisons
between correlated groups were performed using
McNemar exact test. A P value less than .05 was
considered significant. For the analysis we divided
the patients into 2 cohorts: cohort 1 patients took
infliximab originator at the beginning of the study
period and were later switched to the infliximab
biosimilar; and cohort 2 patients were infliximab-
na€ıve and started on the infliximab biosimilar at the
beginning of the study period.RESULTS
Cohort 1: Patients with psoriasis who switched
from the infliximab originator to the
infliximab biosimilar
Thirty patients with psoriasis had ongoing in-
fliximab originator treatment at study initiation (July
1, 2015). The mean PASI score before infliximab
treatment was 29.2. Ten patients also had a diag-
nosis of psoriatic arthritis. The median time on
infliximab originator was 237 weeks (range 14-
576 weeks) (Table I). After switching to the
infliximab biosimilar, treatment was continued on
the same schedule and dosage. The median follow-
up on the biosimilar was 23 weeks (range 13-
33 weeks), with a median number of cycles of 4
(range 2-7). PASI and visual analog scale scores
were not significantly different (McNemar exact
test; P [ .05) before the switch to the biosimilar
and at the end of the observation period (January
20, 2016).These results are similar to those published for
other diseases such as rheumatoid arthritis and
ankylosing spondylitis, where the infliximab bio-
similar proved its efficacy.9,10
About 50% of patients with psoriasis who start
infliximab have to discontinue treatment within the
first year because of loss of efficacy attributed to anti-infliximab antibodies and a
faster drug clearance.11-13
Cohort 1 patients had a
long-lasting response to the
infliximab originator before
the switch, with most pa-
tients receiving the drug for
more than 12 months (Table
I). This makes occurrences of
adverse events and the
development of immunoge-
nicity in these patients un-
likely. During follow-up, 1
patient developed herpes
zoster and his symptoms
resolved completely after a
7-day course of systemic va-lacyclovir hydrochloride and paracetamol. No other
adverse events were observed.
Our study shows that patients with psoriasis and a
long-lasting response to the infliximab originator can
be switched to the infliximab biosimilar without
experiencing a significant change in clinical
response or additional adverse events.Cohort 2: Infliximab-na€ıve patients who
started treatment with an infliximab
biosimilar
Cohort 2 consisted of 5 patients with moderate to
severe plaque psoriasis for whom at least 1 systemic
treatment failed and who did not receive infliximab
before the beginning of the study (Table II). The
mean PASI score at the beginning of the treatment
was 27.3. All cohort 2 patients received the infliximab
biosimilar starting with an induction phase (week 0,
2, 6). Four of 5 patients reached 75% improvement
from baseline PASI score at week 10. Although only 5
patients were treated, we hypothesize that the PASI
reduction by the infliximab biosimilar is in line with
that reported for the infliximab originator.2DISCUSSION
Despite the limitations of our study (low sample
size, limited follow-up time) we conclude that the
infliximab biosimilar is an appealing treatment
choice for patients affected by plaque psoriasis.
Considering possible price differences between the
Table I. Clinical data of patients with psoriasis treated with infliximab originator who switched to the infliximab
biosimilar
No. Gender Age, y
Psoriatic
arthritis
PASI score before
infliximab originator
Time on infliximab
originator before switch, wk
No. of infliximab
biosimilar cycles
Follow-up after
switch, wk
1 M 68 Yes 15.1 268.86 3 13
2 M 77 Yes 20.3 576.14 2 19
3 M 64 No 15.2 380.57 3 20
4 M 56 No 30.5 211.00 4 23
5 M 47 No 45.2 576.14 3 20
6 M 50 No 30.4 419.71 3 28
7 F 33 No 20.3 106.86 5 24
8 M 40 Yes 15.1 263.14 4 19
9 M 52 No 40.5 176.00 3 20
10 F 51 No 30.4 158.71 5 24
11 M 46 No 40.7 107.14 5 23
12 M 52 No 40.6 443.29 3 20
13 M 52 No 25.4 302.14 3 18
14 M 56 No 20.1 419.71 3 20
15 M 86 No 25.6 471.86 3 20
16 M 52 Yes 12.3 158.71 4 23
17 M 56 Yes 35.7 315.29 6 25
18 M 52 No 40.5 158.71 7 27
19 M 39 No 42.5 263.14 5 25
20 F 55 Yes 14.2 106.57 6 15
21 M 38 No 25.2 158.71 2 25
22 M 51 No 20.3 211.00 5 26
23 M 28 No 45.2 13.71 4 33
24 F 44 Yes 20.6 158.71 2 13
25 M 38 Yes 30.5 158.71 2 13
26 M 51 No 40.2 367.43 5 27
27 M 53 No 30.4 524.00 4 27
28 M 47 Yes 12.3 72.71 5 28
29 M 65 No 25.2 315.29 4 27
30 M 68 Yes 35.5 77.14 5 27
F, Female; M, male; PASI, Psoriasis Area and Severity Index.
Table II. Clinical data of infliximab-na€ıve patients
with psoriasis who start treatment with the
infliximab biosimilar
No. Gender Age, y
Psoriatic
Arthritis
Prior
treatment
PASI score
at study
beginning
PASI score
at study
end
31 Male 27 No M, C, A 26.8 5.1
32 Male 48 No C, M 23.1 4.7
33 Male 28 No M 30.4 8.5
34 Male 47 No C 31.2 5.4
35 Male 45 No M, C 25.2 4.3
A, Adalimumab; C, cyclosporine; M, methotrexate; PASI, Psoriasis
Area and Severity Index.
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